We are developing cutting edge immunotherapies based on Toll-Like Receptor (TLR) biology and its ability to modulate the immune system. Learn More >
Through our expertise in TLR biology we have designed compounds that stimulate multiple innate mechanisms of tumor killing and development of immune memory associated with tumor-specific antigens. Learn More >
HEPLISAV-B is an investigational adult hepatitis B vaccine that combines hepatitis B surface antigen with a proprietary TLR9 agonist to enhance the immune response. HEPLISAV-B is currently in Phase 3 clinical trials.